The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
What more can be done to improve treatment for patients with polycythemia vera?
Featured:
Haifa Kathrin Al-AliWhat more can be done to improve treatment for patients with polycythemia vera?
During the European Hematology Association (EHA) 2024 Hybrid Congress, the MPN Hub was pleased to speak with Haifa Kathrin Al-Ali, University Hospital Halle, Halle, DE. We asked, What more can be done to improve treatment for patients with polycythemia vera?
Al-Ali provides an overview of how to improve treatment and outcomes for patients with polycythemia vera, opening with a discussion of the latest advancements in the field and key areas for improvement. Al-Ali shares insights on symptoms management, risk stratification, and the potential applications for machine learning and artificial intelligence in MPN. This interview concludes with a discussion of the goals for treatment and how these may vary between patients and physicians, highlighting the importance of the patient voice in the treatment of MPN.
Listen to the podcast here:
What more can be done to improve treatment for patients with polycythemia vera?
Your opinion matters
On average, how many patients with myelofibrosis do you see in a month?
